With the production of new data indicating short term post-chemotherapy survival of cancer patients with lymphopenia characterized by a loss of CD4 T cells or repertoire diversity (divpenia), a new therapeutic paradigm is beginning to open based on the role of the immune system in treating these cancer patients (Fig. 4). Here, CD4 is linked to lymphopenia.